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We provide an insight into the role Drosophila has played in elucidating neurophysiological perturbations associated with
Parkinson’s disease- (PD-) related genes. Synaptic signalling deficits are observed in motor, central, and sensory systems. Given
the neurological impact of disease causing mutations within these same genes in humans the phenotypes observed in fly are of
significant interest. As such we observe four unique opportunities provided by fly nervous system models of Parkinson’s disease.
Firstly,Drosophilamodels are instrumental in exploring the mechanisms of neurodegeneration, with several PD-related mutations
eliciting related phenotypes including sensitivity to energy supply and vesicular deformities. These are leading to the identification
of plausible cellular mechanisms, which may be specific to (dopaminergic) neurons and synapses rather than general cellular
phenotypes. Secondly, models show noncell autonomous signalling within the nervous system, offering the opportunity to develop
our understanding of the way pathogenic signalling propagates, resembling Braak’s scheme of spreading pathology in PD.Thirdly,
the models link physiological deficits to changes in synaptic structure. While the structure-function relationship is complex, the
genetic tractability of Drosophila offers the chance to separate fundamental changes from downstream consequences. Finally, the
strong neuronal phenotypes permit relevant first in vivo drug testing.
1. Introduction
The discovery of inherited forms of Parkinson’s disease (PD)
provided a sea-change in our understanding of the disease.
Importantly, new genetic animal models were created, based
on the ever-expanding pool of PD-related pathogenic muta-
tions. Commentators have noted that many mouse models
have been disappointing, showing weak phenotypes [1, 2].
On the other hand, fly models have shown strong PD-related
phenotypes, including reduced locomotion, loss of dopamin-
ergic (DA) neurons, problems with reactive oxygen species,
mitochondrial dysfunction, and protein aggregation [3]; for
review see [4]. Fly models have been successful because
the uniquely powerful genetic toolbox [5, 6], notably the
GAL4-UAS system [7], has allowed tissue or neuron specific
expression of dominant mutations (e.g., 𝛼-synuclein-A30P
or LRRK2-G2019S) or RNA interference constructs (RNAi,
e.g., against parkin). For recessive mutations, the toolbox
facilitates generation of targeted pointmutations or deletions.
Additionally, the sharing of fly stocks and related reagents
is common practice. A key outcome of this toolbox was the
identification of common cellular effects across several PD-
relatedmutations. For example, the “droopywing” phenotype
was instrumental in the discovery that parkin and Pink1
interacted at the mitochondria [8, 9]. A number of other
PD-related genes (including Fbxo7 [10], TRAP1 [11], LRRK2
[12], and 𝛼-synuclein [13]) have since been implicated in this
pathway suggesting a high degree of homology in the disease
and fly model. Fly models have also linked 𝛼-synuclein with
Tau [14], extending the usefulness of Drosophila as a model.
Furthermore, the fly models have begun to provide an in vivo
testbed for drugs developed in biochemical or cell culture
assays [15, 16].
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Figure 1:The consistentDrosophila larval NMJ. (a)Dissection of third instarDrosophila larvae reveals a distinct body plan, which is consistent
between all larvae, comprised of 14 segments, 3 of which define the head and mouth region, 3 thoracic segments (T1–T3), and 8 abdominal
segments (A1–A8; segment A3 indicated by the white dotted line). The CNS is outlined in magenta, the main nerve trunks indicated by
magenta arrows. The trachea, which supply oxygen to the nerves and muscles remain intact, and two are indicated by the light cyan arrow.
(b) Abdominal segments A2–A7 are composed of 2 bilaterally symmetrical hemisegments, each of which displays an archetypal structure
comprising 30 distinct muscles. (c) These hemisegments have been extensively studied with a number of specific NMJs utilised as model
synapses for a range of experimental purposes. Here we show muscle 6/7 (hemisegment A3). This muscle pairing has been extensively used
for electrophysiological experiments due to the large size and accessibility of the NMJ, with the presynaptic motor neuron clearly visible
innervating muscles 6 and 7. In this diagram we demonstrate how a suction electrode can be used to stimulate a single segmental nerve whilst
recordings are made from muscle 6 (the larger of the pair).
Flies, like vertebrates, have DA neurons in the CNS [17].
The similarity between flies and vertebrates is also evident
in the roles that dopamine plays in the fly CNS: it mod-
ulates locomotion, feeding, sleep/circadian rhythms, and
learning [18]. However, relatively little is known about the
physiological changes which occur in the nervous system
when PD-related genes are manipulated. Almost all the
neurophysiological evidence comes from analysis of recessive
mutations in Pink1 and parkin, and of the dominant gain of
kinase function, LRRK2-G2019S. Our aim here is to review
the evidence of nervous system dysfunction in these models,
examining the changes in resting and synaptic potentials and
linking these changes to behavioural deficits and loss of DA
neurons. We also suggest how the combination of genetics
and physiology in flies may provide novel insights into the
progression of the excitotoxic neurodegenerative cascade.
Despite the small size of Drosophila, three physiologi-
cally tractable preparations are commonly used: the larval
neuromuscular junction (NMJ), locomotory central pattern
generator (CPG), and visual electroretinogram (ERG). All
three preparations have been widely explored in wild-type
Drosophila and in a range of non-PD settings. This provides
a wealth of background information, which permits us to
evaluate the impact of PD-mutations on the physiology of the
motor, central, and sensory synapses.
2. The Drosophila Larval Neuromuscular
Junction, a Model Synapse
The Drosophila larval NMJ is a well-characterised model
synapse that has proved a highly amenable and success-
ful tool to study synaptic development and neurotrans-
mission [19]. In addition, the larval NMJ shows a sig-
nificant degree of structural and functional similarity to
vertebrate central synapses. For example, both vertebrate
excitatory central synapses and Drosophila larval NMJs are
glutamatergic and many of the molecules used in synap-
tic transmission are the same (see, e.g., [20] for details).
However, in contrast to vertebrate central synapses, both
the pre- and postsynaptic components of the larval NMJ
are distinctly identifiable, accessible, and invariable from
larva to larva, displaying archetypal structure and consistent
neurophysiological responses (Figure 1). This means that
NMJs can be easily compared between genotypes, pro-
viding a reliable model to investigate neurophysiological
defects associated with disease causing mutations. This level
of consistency would not be possible in vertebrate CNS
synapses. Here we look to collate neurophysiological data,
obtained using the larval NMJ as a model synapse, in studies
looking at Drosophila mutants associated with Parkinson’s
disease.
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Figure 2: Pink1 mutants display a progressive decline in synaptic transmission under high frequency stimulation. ((a)i-ii) Pink1 (Pink1B9)
mutants showed no perturbation to basal neurotransmitter release properties, with no significant difference in the amplitude of evoked
excitatory junction potentials (EJP) observed between Pink1mutants and controls. ((a)iii) Under high frequency stimulation (10min, 10Hz)
Pink1mutants showed a substantial, progressive decline in synaptic transmission when compared to controls. ((b)i–iii) Pink1mutants showed
no significant difference in spontaneous miniature EJP (mEJP) amplitude (i-ii) or frequency (i and iii) when compared to controls. Adapted
from [21].
3. NMJ Analysis Reveals Synaptic
Perturbations in Parkinson’s Mutant Flies
The most detailed analysis comes from the recessive, loss
of function, mutation Pink1B9 (Figure 2). These have a
substantial progressive decline in synaptic transmission in
response to high frequency stimulation at the larval NMJ
[21]. However, there is no perturbation to basal release
characteristics (i.e., no deficits in neurotransmitter release,
spontaneous release frequency, or response amplitude) in
this Pink1 mutant. By using FM dyes to selectively label
synaptic vesicle pools, it was demonstrated this decline
resulted from a failure tomobilise the synaptic vesicle reserve
pool. This phenotype could be, at least partially, rescued
by administration of ATP to the synapse, supporting a role
for Pink1 in maintaining energy supply in periods of peak
demand. A subsequent study supported this hypothesis,
showing that Pink1 had a role in the homeostatic regulation
of mitochondria. Pink1modulated the activity of the electron
transport chain, complex I [22]. In mouse, phosphopro-
teomic analysis in mouse revealed that Pink1 nulls fail to
phosphorylate mitochondrial complex I subunit NdufA10
(NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 10)
at Ser250. The consequences of this for synaptic transmission
were explored in Drosophila, where the progressive decline
in synaptic transmission seen in Pink1mutants was alleviated
by expression of a phosphomimetic NdufA10. Additionally,
phosphomimetic NdufA10 expression restored mitochon-
drial membrane potential and rescued both ATP synthesis
and mobilisation of the synaptic vesicle reserve pool. The
fly Pink1 model has also proved useful in suggesting a novel
therapeutic strategy, as the defects in synaptic mitochondrial
membrane potential were rescued by feeding Drosophila on
bacteria synthesising vitamin K
2
[16].
As with Pink1, mutations in parkin are associated with
recessive, early-onset, and familial PD. In addition, genetic
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Figure 3: Parkin mutants display depolarisation of the muscle resting membrane potential coupled with reduced EJP amplitudes. (a)
Spontaneous excitatory junction potentials (EJPs) were recorded from muscle 6 or 7. The mean resting potential and amplitude of the EJPs
in the parkin mutant (parkZ3678/parkin25) were ∼12mV more positive than in wild-type (CS/w1118). In this recording both the Is and Ib EJPs
are visible: both were reduced in the parkinmutant. (b)The spontaneous miniature EJPs (mEJPs) are smaller in the parkinmutant, as shown
by these two recordings made at the same RMP. (c) Quantification of the change in resting membrane potential (RMP) in the parkinmutant,
and the rescue by expression of Drosophila wild-type parkin in the muscle (G14 GAL4), but not the nerve (elav3e1 GAL4). (d) The plot of the
size of Is EJP as a function of RMP shows that the more negative the RMP, the larger the EJP. However, at any chosen RMP, the wild-type EJP
is bigger than those recorded from the parkin mutant. Note that all the green data points lie above the red regression line plotted through
the parkin data. Expressing parkin in the nerves leads to data points that significantly lie above the red regression line, 𝜒2
1df = 7.1, 𝑃 < 0.01,
showing effective rescue of the phenotype. parkin expression in the muscle leads to data distributed symmetrically about the regression line,
no rescue. Data from [23] with (d) showing some data reanalyzed.
manipulations in the fly revealed interacting mitochondrial
phenotypes in the muscle [8, 9]. As such it is not sur-
prising that parkin mutant larvae, like Pink1 larvae, also
show perturbed synaptic transmission: a reduction of both
evoked and spontaneous (mini) excitatory junction potential
(EJP) amplitudes, along with depolarisation of the resting
muscle membrane potential [23] (Figure 3). Reduced synap-
tic transmission is likely the result of impaired glutamate
release, potentially due to the observed changes in synaptic
morphology and/or ATP depletion. This in turn further
alludes to an impairment of aerobic respiration in mutants
implicated in Parkinson’s disease.
Since the G2019S mutation in LRRK2 is the most com-
mon cause of late-onset PD, two groups have examined
the impact of overexpressing LRRK2-G2019S on the fly NMJ.
Lee et al. [24] compared pre- and postsynaptic expression
of the normal human form hLRRK2 with the pathogenic
human LRRK2-G2019S transgene at the larval NMJ. They
demonstrated little effect postsynaptically with no signifi-
cant alteration in any of the parameters measured (mEJP
frequency, amplitude, quantal content, or EJP amplitude). In
contrast, presynaptic expression elicited a significant increase
in mEJP frequency, coupled with a reduced quantal content.
Matta et al. [25] also examined the effect of LRRK2-G2019S
overexpression at the NMJ, using FM dyes to show that
ubiquitous expression impeded synaptic vesicle endocytosis.
The fly homolog to LRRK2 is known as Lrrk. The homo-
zygous loss-of-function Lrrk mutant also presents with
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deficits in synaptic transmission, characterised by a signifi-
cant depletion in EJP amplitudes [24]. This phenotype
was partially rescued by presynaptic, but not postsynaptic,
expression of Lrrk. Nonetheless, mEJP amplitudes showed
no difference to wild-type, implying a decreased quantal
content. Lrrk mutants also displayed a significant increase
in mEJP frequency. In a second study, using a different
Lrrk loss-of-function mutant, no difference in EJP amplitude
was found between Lrrk loss-of-function mutants and wild-
types at baseline conditions, and mEJPs were larger [25].
This discrepancy in synaptic physiology may be due to the
fact that different Lrrk mutant alleles were used by the two
groups or may be due to differences in genetic background,
as previous studies on Lrrk mutants have reported different
lifespan phenotypes [26–28].
An important advance was derived from the observa-
tion that Lrrk mutants showed a progressive rundown with
repetitive stimulation, indicating a link to defective synaptic
vesicle cycling and enlarged vesicle structures within the
synapse at an ultrastructural level [25].This was due to LRRK
phosphorylating endophilin-A (EndoA) at serine 75 in order
to modulate EndoA dependent membrane deformation and
endocytosis of the synaptic membrane. This was confirmed
when heterozygous loss-of-function EndoAmutants rescued
the progressive decline in synaptic transmission observed
in Lrrk mutants during high frequency stimulation. Simi-
larly presynaptic overexpression of EndoA could potentiate
reduced synaptic membrane endocytosis observed using
FM1-43.
A recent study of the dominant gene, 𝛼-synuclein,
reported a similar phenotype as a result of presynaptic over-
expression of wild-type human𝛼-synuclein, eliciting enlarged
synaptic vesicles and elevated mEJP amplitudes [29]. This
was reverted by expression of the endosomal recycling factor
Rab11.This data is of considerable interest, as flies do not have
a close𝛼-synuclein homolog but clearly respond to expression
of human 𝛼-synuclein.
In addition to the study of synaptic transmission, the
Drosophila larval NMJ has proven highly amenable and suc-
cessful in the study of synaptic growth and development. For
example, perturbed NMJ morphology and growth have been
observed in numerousmodels of neurodegenerative diseases,
including Alzheimer’s and frontotemporal dementia as well
as PD [24, 30, 31]. However, analysis of PD-related mutants
reveals NMJ growth phenotypes do not consistently correlate
with synaptic transmission phenotypes observed. For exam-
ple, whilst Lrrk mutants and presynaptic expression of the
pathogenic LRRK2-G2019S transgene both elicit a reduced
quantal content and increased mEJP frequency, Lrrkmutants
display a synaptic overgrowth phenotype and the LRRK2-
G2019S NMJs are significantly undergrown [24]. Similarly,
whilst both pre- and postsynaptic expression of LRRK2-
G2019S elicited synaptic undergrowth, only presynaptic
expression perturbed synaptic transmission.The observation
of such differences between genotypes may allude to different
molecular mechanisms implicated in pathology and, thus,
may provide greater insight into the disease than by looking
at synaptic transmission or NMJ morphology alone.
4. Examination of Rhythmic Patterns Reveals
CNS Defects in Parkinson’s Mutant Flies
Rhythmic movements depend on patterned output from
the CNS to the motoneurons and thence to the muscles.
A similar pattern usually persists when sensory input is
reduced, though often at a lower frequency [32]. This led to
the idea of a central pattern generator (CPG). These have
been directly demonstrated by isolating the CNS in a dish
of saline and recording the rhythmic pattern in a number
of systems, both vertebrate and invertebrate [33]. The persis-
tence of a “fictive crawling” pattern when sensory input was
reduced inDrosophila larvae [34–36] has suggested that their
locomotion depends on a CPG. The full details of the larval
crawling CPG remain to be elucidated, but the motoneurons,
glutamatergic, and cholinergic interneurons contribute [37]
along with contributions from neurons expressing the clock
gene period [38].
In parkin mutants, the speed of locomotion was slowed
by ∼30% [23]. Using a larval extensometer, it was shown that
this was due to a reduction in the frequency of peristalsis,
while the strength of the contractions remained unchanged
(Figure 4). Restoring parkin to the nervous system rescued
the frequency of contractions. In a semi-intact preparation,
the segmental nerves were severed, and the frequency of
bursts of action potentials was recorded in the motoneurons’
axons. The parkin mutants showed a 50% reduction in
bursting rate. All this implies the parkin defect in these
young Drosophila is principally in the CNS and that the
muscles are not yet dysfunctional. In adult parkinflies,muscle
degeneration gradually develops, and the flies become unable
to maintain their normal wing posture [39].
In order to test the hypothesis that neural dysfunction
precedes muscle degeneration, we have recorded from the
motoneuronal axons after isolating the CNS. These record-
ings still show bursts of action potentials, though the fre-
quency of these bursts is much lower than the frequency of
peristaltic waves in the intact wild-type larva. Importantly,
parkin mutants show a 30% reduction compared to wild-
type controls (Figure 4). Application of 1mM dopamine to
the bath restored the bursting pattern of parkin nerves to
wild-type levels but did not affect wild-type larvae. The
frequency of the compound action potentials within the
burst is not affected by the parkin mutations, suggesting
the motoneurons are firing at a similar rate. We conclude
that while parkin may reduce synaptic potentials generated
from (and between) interneurons, it is possible that parkin
depolarises the motoneurons (as it does the muscles), so
compensating for changes in the interneuronal output.
5. Examination of Electroretinograms
Reveals Synaptic Defects in Parkinson’s
Mutant Flies
Although still generally described as a movement disorder,
PD is a complex multisystem disorder with patients experi-
encing a range of symptoms with both motor and nonmotor
features. For example, a variety of visual associated defects
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Figure 4: The parkin mutation slows the locomotor CPG, with rescue by neuronal expression of parkin or application of DA to the CNS.
(a) Recordings with a larval extensometer (i) show that (ii–iv) the frequency (controlled by the CNS) but not the amplitude (controlled
by the muscle performance) is affected by the parkin mutant (parkZ3678/parkin25). The contraction frequency is rescued by expression of
Drosophila wild-type parkin in the nerve (elav3e1 GAL4), but not the muscle (G14 GAL4). (b) In a semi-intact preparation, with en-passant
nerve recordings, the frequency of bursting is reduced in the parkinmutant. (c) In the isolated CNS, the fictive locomotion rhythmic bursting
pattern is also reduced in the parkin mutant and rescued by application of dopamine (DA, 1mM in HL-3 saline supplemented with 3mM
ascorbic acid to reduce oxidation). Data in (a) and (b) from [23], with original recordings in (c).
ranging from dry eyes to abnormal light adaptation and com-
plex hallucinations have all been reported in patients with
PD [40]. Through the use of tyrosine-hydroxylase staining
amacrine cells in the human retina have been identified as
dopaminergic [41]. Retinal dopamine can be reduced in PD
patients [42]. Therefore, some of the visual consequences of
PD may originate in the retina, where dopamine is known to
play a major role in signal regulation [43, 44].
At first sight, flies eyes seem quite unlike those of
vertebrates. However, using silver staining, Cajal and Sanchez
demonstrated that many of the neuronal circuits in the verte-
brate and fly eye are fundamentally conserved [45]. This has
since been corroborated using more advanced cytochemical
approaches [46]. Of importance, like vertebrates, flies also
have DA neurons in their visual system [47, 48] and DA
circuits modulate fly vision [49–51].
Strong overexpression of some PD-related transgenes in
the retina leads to developmental abnormalities, including 𝛼-
synuclein [3, 13], LRRK2 [52], or tau [14]. To test for abnormal
physiology within the visual system, flash electroretinograms
(fERGs) could be readily deployed.The anatomy of the fly eye
makes it relatively easy to record fERGs; thus, the Drosophila
ERG has been utilised for over 50 years, proving to be highly
important in the characterisation of many of the key genes
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involved in phototransduction and the identification of over
200 ERG-defective mutants [53, 54]. However, we are not
aware of physiological studies of these systems.
Hindle et al. [49] adopted an alternate approach: rather
than using strong expression in the retina, they expressed the
dominant LRRK2-G2019S mutation in just the DA neurons
(DA → G2019S) and then used fERGs to analyse visual neu-
rophysiology. The key result is that dopaminergic expression
of LRRK2-G2019S leads to a reduction in all components of
the fERG at 28 days old; no loss of response is seen with
dopaminergic expression of the wild-type hLRRK2 gene. The
decline in visual function is sensitive to the G2019Smutation
as dopaminergic expression of other mutations within the
LRRK2 gene, known to be pathogenic or to segregatewith PD,
shows no significant reduction in the fERG amplitude. Using
other GAL4 drivers to express LRRK2-G2019S ubiquitously
or in specific tissues of the eye, including the photoreceptors
or lamina neurons, shows that the visual decline is specific for
the expression of LRRK2-G2019S in DA neurons.
Whilst externally the eyes of DA → G2019S flies appear
normal, the functional decline in vision of these flies is
accompanied by anatomical neurodegeneration throughout
the visual system. This includes disorganised retinas and
frequent vacuoles appearing in the second- and third-order
visual neuropils (lamina and medulla) [49]. Antibody stain-
ing reveals an increase in autophagy and apoptosis around
the microvilli of the photoreceptors of old DA → G2019S
flies. Electron micrographs show that the photoreceptor
mitochondria of these flies become fragmented, swollen, and
the cristae wider. DA neurons innervating the optic system
were unperturbed in aged DA → G2019S flies suggesting
that the loss of visual function and degeneration of the
photoreceptors precede any loss of dopaminergic innervation
of the visual lobes.
Increasing the demands on the visual system either
through keeping flies in a pulsating light incubator or geneti-
cally through the introduction of the electrical-knock-in
(EKI) transgene into the DA neurons to make them more
active accelerates the decline in visual function due toG2019S
expression [49].
The accelerated degeneration of the visual system through
increased neuronal activity led to the hypothesis that young
DA → G2019S flies could have amplified neuronal responses
compared to wild-type flies. To test this hypothesis the
steady-state visually evoked potential (SSVEP) method used
in human visual electrophysiologywas successfully translated
to flies [15]. This technique is more sensitive than the widely
used fERG because responses to many stimulus events are
averaged together and out-of-band noise is eliminated from
the analysis.
One day after eclosion, DA → G2019S flies had a dra-
matically increased contrast sensitivity compared to controls
expressing the wild-type hLRRK2 or to those not expressing
any transgene in their DA neurons [15]. The increased sensi-
tivity of the DA → G2019S flies is thought to originate in the
photoreceptors and is inherited by the second-order lamina
neurons. These results, taken with Hindle’s observations,
suggest that a period of hyperactivity of the visual system
occurs in youngDA → G2019S flies.This starts an excitotoxic
cascade (Figure 5), in which the flies soon start to suffer
from an increased sensitivity to energy demand, followed
by a cascade of degenerative events including apoptosis
and autophagy. In old flies, the photoreceptors and their
mitochondria have degenerated to such a degree that the
vision of these flies is severely defective.
A key question is whether compounds that rescueG2019S
phenotypes in cellular or in vitro assays also work in vivo.
As this mutation occurs in the kinase domain of hLRRK2,
flies were fed on inhibitors targeted at LRRK2-G2019S. One
of these compounds, LRRK2-IN-1, has previously been iden-
tified as aLRRK2 kinase inhibitor [55].The second compound
was a novel LRRK2 inhibitor, BMPPB-32 [15]. Both LRRK2-
IN-1 and BMPPB-32 rescue the initial hyperactivity seen
in young flies expressing G2019S in their DA neurons: the
photoreceptor and neuronal responses are rescued to levels
comparable to control flies. To test for off-target effects,
the SSVEPs of flies with no Lrrk were measured. When
LRRK2-IN-1 is given to these flies the SSVEP responses
are significantly increased indicating that in vivo as in vitro
LRRK2-IN-1 is binding to other kinases. When BMPPB-32
is applied there are no significant changes of the Lrrkmutant
flies suggesting this compound does not have severe off-target
effects and may be a promising candidate for future drug
trials.
Previously we tested these drugs by applying them
throughout the entire lifespan (larva and fly). We have now
extended this data by applying BMPPB-32 only after the
time point where we see a neurophysiological phenotype,
the start of adult life (Figure 5). This mimics the situation
of a PD patient, who may only wish to start taking drugs
once symptoms become apparent. In this experiment, larvae
were raised on drug-free food, and the adult flies were given
the drug on the day of eclosion. The adults were kept in
a pulsating light incubator for 7 days. Already, the visual
physiology of the DA → G2019S flies was severely reduced
(Figure 6) with marked loss of the photoreceptor response
(down by 70%). The reduction in signalling in the second-
and third-order neurons was even more severe (lamina:
85%; medulla: 90%), suggesting a key synaptic phenotype.
Control flies had visual responses indistinguishable from the
younger, 3-day-old, flies. Feeding BMPPB-32 significantly
improves the visual function of 7-day-old DA → G2019S
flies, restoring the visual response to ∼70% of control flies
(Figure 6). Although the mean visual response in the control
flies fed with BMPPB-32 appears slightly lower than the
drug free controls, this difference is not statistically signifi-
cant.
More recently, we have also shown that a second drug,
UDCA (ursodeoxycholic acid), which rescues mitochondrial
function in LRRK2-G2019S fibroblasts [56], also ameliorates
the DA → G2019S visual neurophysiological deficit [57].
The impact of providing BMPPB-32 or UDCA to DA →
G2019S flies after a phenotype has started to develop sug-
gests that drugs like this may provide a disease modifying
therapy as well as a preventative therapy. As UDCA is
already licensed for liver disease, this is an exciting develop-
ment.
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Figure 5: An excitotoxic cascade is initiated by the dopaminergic expression of the human LRRK2-G2019S transgene (DA → G2019S). In
young, 1-day-old DA → G2019S flies, the eyes show much greater contrast sensitivity than the controls. At 3 days, the visual sensitivity
measured by a flash electroretinogram (fERG) is indistinguishable from control flies. At 10 days, the DA → G2019S flies are more sensitive
to energy demands than controls. Energy demand is increased by either treatment with flashing light or knockdown of potassium channels.
By 21 days, the DA → G2019S eyes show evidence of apoptosis (anticleaved-caspase-3 staining). Old flies, 28 days, show little photoreceptor
response, extensive vacuoles, and deformed mitochondria, showing loss of both function and structure. Data and exact genotypes in [15, 49].
6. Conclusion
Our analysis shows that themanipulation of PD-related genes
in flies has revealed deficits in motor, CNS, and sensory
synaptic signalling.Whilst relatively few groups are currently
investigating these neurophysiological deficits, and thus some
findings await independent confirmation, the observations
remain striking. Furthermore, given the neurological impact
of such mutations in the human population, we see four
unique opportunities provided by the fly neurophysiology.
Firstly, these phenotypes are instrumental in exploring
the links between common physiological problems (e.g.,
vesicular signalling, sensitivity to energy supply) and neu-
rodegeneration. These are leading to the identification of
plausible cellular pathways (and perhaps also possible part-
ners, e.g., endophilin-A, NdufA10, Rab11). Flies provide a
major opportunity here to separate the normal interactions in
neuronal and synaptic function from generic cellular effects.
The similarity in neuronal systems between fly and human,
coupled with the observation of dopaminergic phenotypes in
the fly, offers the potential to identify mechanisms that make
DA neurons more sensitive to PD-related mutations.
Secondly, the models show a noncell autonomous sig-
nalling within the nervous system. This is most evident
in the visual LRRK2-G2019S model, where expression of
the transgene in the DA neurons affects the histaminergic
photoreceptors, and the nondopaminergic second- and third-
order (lamina and medulla) neurons. Other examples of
nonautonomous signalling have been reported in the Lrrk
and parkinmutants. These models therefore offer the oppor-
tunity to develop our understanding of the mechanisms
by which pathogenic signalling expands, for example, by
exosomes, and phenocopy Braak’s view of the gradual spread
of pathology in PD [58].
Thirdly, the physiological data we have reviewed are
often linked to changes in synaptic structure. This is seen
in the parkin and Lrrk mutants, and this may be related
to oxidative stress. While the link between structure and
function is complex, the genetic tractability of Drosophila
offers the chance to use epistatic shielding to determinewhich
changes (in anatomy/physiology) are fundamental andwhich
are downstream consequences.
Finally, the strong neuronal phenotypes have also permit-
ted the development of drug testing in vivo. This has been
seen in both recessive anddominant geneticmodels, with tool
compounds providing successful preventative and possibly
disease modifying therapies.
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Figure 6: Rescue of dopaminergic LRRK2-G2019S visual neurophysiology by BMPPB-32 only applied during adult life. (a) Diagram of the fly
eye, showing the lens (red), photoreceptors (blue), second-order lamina (purple), and third/fourth-order medulla (orange). Dopaminergic
neurons are shown in green.When illuminated with flickering blue light, the overall (field) potential we record is separated by the fast Fourier
transform (FFT) into components corresponding to the photoreceptor, lamina, and medulla neurons, respectively, details in [15]. (b) Larvae
were raised on drug free food and some transferred to food containing 2.5𝜇M of the specific LRRK2 kinase inhibitor BMPPB-32 [15] on
the first day of adult life. After 3 days, the contrast/response function (CRF) of flies expressing LRRK2-G2019S in the dopaminergic neurons
(DA → G2019S) is indistinguishable from flies expressing hLRRK2 or to those not expressing any transgene. BMPPB-32 application has no
effect. (c) At 7 days, the DA → G2019S flies show very much reduced CRFs, well below the controls. BMPPB-32 restores the visual function
to within 30% of the controls. There is no statistically significant effect of this drug on the control genotypes. Genotypes as in [15]; data not
previously published.
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